Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion

Heart and Vessels

Volumn 30, Issue 4, 2015, Pages 490-497

  Cho, Kyoung Im ^a   Kim, Bong Joon ^a   Cha, Tae Joon ^a   Heo, Jung Ho ^a   Kim, Hyun Su ^a   Lee, Jae Woo ^a  

^a Kosin University College of Medicine   (South Korea)

Author keywords

Atrial fibrillation; Electrical cardioversion; Epicardial fat thickness; Statin

Indexed keywords

AMIODARONE; ATORVASTATIN; FLECAINIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPAFENONE;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR PARAMETERS; CARDIOVERSION; COHORT ANALYSIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ELECTROCARDIOGRAM; EPICARDIAL FAT THICKNESS; FEMALE; FOLLOW UP; HEART LEFT ATRIUM; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SINUS RHYTHM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; AGED; DEVICES; ECHOCARDIOGRAPHY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; HEART ATRIUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERICARDIUM; PROGNOSIS; STATISTICAL MODEL;

AGED; ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERICARDIUM; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 84938424323     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0505-8     Document Type: Article

References (39)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57:e101–e198
2. Naccarelli GV, Varker H, Lin J, Schulman KL (2009) Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104:1534–1539
3. Tsadok MA, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Pilote L (2012) Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation 126:2680–2687
4. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW, PROSPER Executive (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 342:d1250
5. Kim SS, Knight BP (2009) Electrical and pharmacologic cardioversion for atrial fibrillation. Cardiol Clin 27:95–107
6. Valencia MJ, Climent PVE, Marin OF, Monmeneu MJV, Martinez MJG, Garcia MM, Ibáñez Criado A, De Burgos García F, Rico F, Sogorb Garri F (2002) The efficacy of scheduled cardioversion in atrial fibrillation. Comparison of two schemes of treatment: electrical versus pharmacological cardioversion. Rev Esp Cardiol 55:113–120
7. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner DJ, Scheiner MA, Lerman BB (2000) Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 101:1282–1287
8. Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J (2003) Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 9:RA225–RA229
9. Ock SY, Cho KI, Kim HJ, Lee NY, Kim EJ, Kim NK, Lee WH, Yeo GE, Heo JJ, Han YJ, Cha TJ (2013) The impacts of C-reactive protein and atrial fibrillation on carotid atherosclerosis and ischemic stroke in patients with suspected ischemic cerebrovascular disease: a single-center retrospective observational cohort study. Korean Circ J 43:796–803
10. Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, Kusunose K, Hotchi J, Ueda Y, Tomita N, Yamaguchi K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M (2013) Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. doi:10.1007/s00380-013-0400-8
11. Bambace C, Sepe A, Zoico E, Telesca M, Olioso D, Venturi S, Rossi A, Corzato F, Faccioli S, Cominacini L, Santini F, Zamboni M (2013) Inflammatory profile in subcutaneous and epicardial adipose tissue in men with and without diabetes. Heart Vessels. doi:10.1007/s00380-012-0315-9
12. Acet H, Ertaş F, Akıl MA, Oylumlu M, Polat N, Yıldız A, Bilik MZ, Yüksel M, Kaya Z, Ulgen MS (2013) New inflammatory predictors for non-valvular atrial fibrillation: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio. Int J Cardiovasc Imaging 30(1):81–89
13. Chao TF, Hung CL, Tsao HM, Lin YJ, Yun CH, Lai YH, Chang SL, Lo LW, Hu YF, Tuan TC, Chang HY, Kuo JY, Yeh HI, Wu TJ, Hsieh MH, Yu WC, Chen SA (2013) Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation. PLoS 8(9):e74926
14. Riesen WF, Engler H, Risch M, Korte W, Noseda G (2002) Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 23:794–799
15. Siu CW, Lau CP, Tse HF (2003) Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92:1343–1345
16. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A (2006) Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97:1490–1493
17. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L (2004) Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 93:780–782
18. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U, Leonetti F (2003) Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res 11:304–310
19. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ (2002) Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834–1840
20. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207–213
21. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046–1051
22. Laufs U, Liao JK (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rho gtpase. J Biol Chem 273:24266–24271
23. Ganotakis ES, Mikhailidis DP, Vardas PE (2006) Atrial fibrillation, inflammation and statins. Hellenic J Cardiol 47:51–53
24. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S (2003) Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92:1379–1383
25. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D (2008) Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 51:828–835
26. Loffredo L, Angelico F, Perri L, Violi F (2012) Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord 12:107
27. Bhardwaj A, Sood NA, Kluger J, Coleman CI (2010) Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. Int J Clin Pract 64:1116–1120
28. Demir K, Can I, Koc F, Vatankulu MA, Ayhan S, Akilli H, Aribas A, Alihanoglu Y, Altunkeser BB (2011) Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. Med Princ Pract 20:464–469
29. Xia W, Yin Z, Li J, Song Y, Qu X (2009) Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 32:1562–1566
30. Veronese G, Montomoli J, Schmidt M, Horváth-Puhó E, Sørensen HT (2013) Statin use and risk of atrial fibrillation or flutter: a population-based case–control study. Am J Ther. doi:10.1097/MJT.0b013e31827ab488
31. Deng W, Bukiya AN, Rodríguez-Menchaca AA, Zhang Z, Baumgarten CM, Logothetis DE, Levitan I, Rosenhouse-Dantsker A (2012) Hypercholesterolemia induces up-regulation of KACh cardiac currents via a mechanism independent of phosphatidylinositol 4,5-bisphosphate and Gβγ. J Biol Chem 287:4925–4935
32. Nakagomi A, Seino Y, Kohashi K, Kosugi M, Endoh Y, Kusama Y, Atarashi H, Mizuno K (2012) Effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function, and long-term prognosis in chronic heart failure patients with dyslipidemia. Circ J 76:2130–2138
33. Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K (1999) Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology 92:21–27
34. Diaz-Peromingo JA, Alban-Salgado A, Garcia-Suarez F, Sanchez-Leira J, Saborido-Frojan J, Iglesias-Gallego M (2006) Lipoprotein(a) and lipid profile in patients with atrial fibrillation. Med Sci Monit 12:CR122–CR125
35. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, ALLHAT Collaborative Research Group (2009) Atrial fibrillation at baseline and during follow-up in ALLHAT (antihypertensive and lipid-lowering treatment to prevent heart attack trial). J Am Coll Cardiol 54:2023–2031
36. Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, Porcellati C, Mannarino E (2001) High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 19:2265–2270
37. Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y (2003) Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 16:938–944
38. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M (2011) Association between lipid profile and risk of atrial fibrillation. Circ J 75:2767–2774
39. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S (2003) Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107:1930–1936